There is continuing local and regional need for high-quality and broadly affordable tools and medicines to effectively diagnose and treat several diseases with high prevalence in emerging markets. Fyodor seeks to address this growing need, beginning with the development of specially-targeted leading-edge technologies for the diagnosis and treatment of malaria.

Fyodor’s technologies envision a complementary suite of affordable at-home or point-of-care diagnostic and biotherapeutic products that will enable the large scale detection and effective treatment of a variety of leading conditions. We focus resources and efforts on short and long term key objectives by leveraging significant assets, and by maintaining and continuing to develop strategic alliances with key government and industry leaders, as well as charitable organizations, throughout the world.

To assume leadership in the diagnosis and treatment of infectious diseases in Africa, our initial target market, Fyodor has identified and continues to build a strong portfolio of products, which are essential to improving the quality of life for people who live in endemic regions.  Fyodor’s core business, and an infrastructure that includes manufacturing and commercial capabilities, provides the basis to continue to identify and maximize opportunities with relevance to the targeted regions and broader commercial markets.